Disitamab vedotin
- Generic Name
- Disitamab vedotin
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2136633-23-1
- Unique Ingredient Identifier
- RB3U3A1S27
- Background
Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
- Indication
用于至少接受过2个系统化疗的HER2过表达局部晚期或转移性胃癌（包括胃食管结合部腺癌）的患者，HER2过表达定义为HER2免疫组织化学检查结果为2+或3+。
- Associated Conditions
- -
- Associated Therapies
- -
Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-01-02
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06187506
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations
- First Posted Date
- 2023-12-29
- Last Posted Date
- 2023-12-29
- Target Recruit Count
- 108
- Registration Number
- NCT06185400
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 198
- Registration Number
- NCT06157892
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Other, Italy
🇺🇸Arizona Cancer Center / University of Arizona, Tucson, Arizona, United States
🇺🇸Chao Family Comprehensive Cancer Center University of California Irvine, Orange, California, United States
A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 116
- Registration Number
- NCT06155396
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳Beijing Obstetrics and Gynecology Hospital ,Capital Medical University, Beijing, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
- Conditions
- Interventions
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT06155383
- Locations
- 🇨🇳
Nanfang Hospital, Guangzhou, Guangdong, China
🇨🇳Shandong Cancer Hospital & Institute, Jinan, Shangdong, China
🇨🇳Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Registration Number
- NCT06105008
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
🇨🇳Binghe Xu, Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
🇨🇳Hunan Cancer Hospital, Changsha, China
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Shanghai East Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06078982
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, China
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
- Conditions
- Interventions
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT06003231
- Locations
- 🇮🇹
Fondazione IRCCS San Gerardo dei Tintori, Monza, Other, Italy
🇬🇧Guy's and St Thomas' NHS Foundation, London, Other, United Kingdom
🇺🇸Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona, United States
RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression
- Conditions
- Interventions
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05957757
- Locations
- 🇨🇳
Ethics Committee of Shanghai Renji Hospital, Shanghai, Shanghai, China
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05940896
- Locations
- 🇨🇳
Shandong Cancer hospital &Institute, Jinan, Shandong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.